The Neurofibromatosis Therapeutic Acceleration Program (NTAP) (www.n-tap.org) is a philanthropic research entity based at Johns Hopkins University School of Medicine dedicated to the discovery of therapeutics for the peripheral nerve tumors that afflict people with Neurofibromatosis Type 1 (NF1).
They have announced a Request for Applications for up to 15 funded projects. Funded projects are anticipated to last from 12-36 months and require $300,000-$1,000,000 per project. Investigators can request funding or duration above or below this range with appropriate justification.
Areas of special interest include:
- Investigate the processes underlying the stages of cNF initiation, progression, maintenance and senescence.
- Identify and validate therapeutic candidates across the various stages and expressions of cNF.
- Identify or validate non-invasive approaches in humans and preclinical systems for detection and assessment of growth or response of cNF.
- Define or validate key variables and endpoints for cNF clinical trials.
- Develop the infrastructure for patient-driven engagement programs to enable registries and rapid enrollment into clinical trials for cNF.
